Exenatide (Exendin-4)–Induced Pancreatitis

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944

Untitled work

Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560

Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

Dore, D. D., Seeger, J. D., & Chan, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 324

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin

Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 319

Drug-induced acute pancreatitis: a review.

Jones, M. R., Hall, O. M., Kaye, A. M., & Kaye, A. D. (2015) · PubMed Central · Cited by 235

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189

Glycaemic control in type 2 diabetes: Targets and new therapies

Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190

The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent

Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166

Adverse drug reactions of GLP-1 agonists: A systematic review of case reports

Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145

A cohort study of acute pancreatitis in relation to exenatide use

Dore, D. D., Bloomgren, G., Wenten, M., Hoffman, C., Clifford, C. R., Quinn, S. G., Braun, D. K., Noel, R. A., & Seeger, J. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01376.x · Cited by 144

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

Engel, S. S., Williams‐Herman, D., Golm, G. T., Clay, R. J., Machotka, S. V., Kaufman, K. D., & Goldstein, B. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02382.x · Cited by 143

Systems Pharmacology of Adverse Event Mitigation by Drug Combinations

Zhao, S., Nishimura, T., Chen, Y., Azeloglu, E. U., Gottesman, O., Giannarelli, C., Zafar, M. U., Bénard, L., Badimón, J. J., Hajjar, R. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006548 · Cited by 135

Exenatide and Rare Adverse Events

Cure, P., Pileggi, A., & Alejandro, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707137 · Cited by 134

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

Madsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 129

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

Williams‐Herman, D., Round, E., Swern, A. S., Musser, B. J., Davies, M. J., Stein, P. P., Kaufman, K. D., & Amatruda, J. M. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-14 · Cited by 128

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

Raschi, E., Piccinni, C. P., Poluzzi, E., Marchesini, G., & Ponti, F. D. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0340-7 · Cited by 126

The Human GLP-1 Analog Liraglutide and the Pancreas

Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 124

Update on incretin hormones

Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 122

Drug-Induced Acute Pancreatitis

Kaurich, T. (2008) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2008.11928366 · Cited by 120

Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations

Wolfe, D. M., Kanji, S., Yazdi, F., Barbeau, P., Rice, D. B., Beck, A., Butler, C., Esmaeilisaraji, L., Skidmore, B., Moher, D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231883 · Cited by 118

Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure

Yoon, G., Kim, Y., & Song, J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104615 · Cited by 109

Exenatide: a review from pharmacology to clinical practice

Gentilella, R., Bianchi, C., Rossi, A., & Rotella, C. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01018.x · Cited by 108

Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 103

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 94

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis

Vrang, N., Jelsing, J., Simonsen, L., Jensen, A. E., Thorup, I., Søeborg, H., & Knudsen, L. B. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00182.2012 · Cited by 92

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

Tatarkiewicz, K., Smith, P. A., Sablan, E. J., Polizzi, C. J., Aumann, D. E., Villescaz, C., Hargrove, D. M., Gedulin, B. R., Lu, M. G. W., Adams, L., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00479.2010 · Cited by 91

Exenatide efficacy and safety: a systematic review

Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02790.x · Cited by 90

Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus

Sheffield, C. A., Kane, M. P., Busch, R., Bakst, G., Abelseth, J. M., & Hamilton, R. A. (2008) · Endocrine Practice · doi:10.4158/ep.14.3.285 · Cited by 86

Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population

Romley, J. A., Goldman, D. P., Solomon, M. D., McFadden, D. L., & Peters, A. L. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0075 · Cited by 85

LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes

Steinberg, W. M., Nauck, M. A., Zinman, B., Daniels, G. H., Bergenstal, R. M., Mann, J. F. E., Ravn, L. S., Moses, A. C., Stockner, M., Baeres, F. M. M., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000229 · Cited by 80

Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner

Zhao, H., Wei, R., Wang, L., Tian, Q., Tao, M., Ke, J., Liu, Y., Hou, W., Zhang, L., Yang, J., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00017.2014 · Cited by 80

Drug induced acute pancreatitis: Does it exist?

Tenner, S. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16529 · Cited by 75

GLP1 and cancer: friend or foe?

Vangoitsenhoven, R., Mathieu, C., & der Schueren, B. V. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0111 · Cited by 77

Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis

Ayoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 78

Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71

Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning

Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71

GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You

Butler, P. C., Dry, S., & Elashoff, R. M. (2010) · Diabetes Care · doi:10.2337/dc09-1902 · Cited by 69

Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications

Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 70

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Butler, P. C., Matveyenko, A. V., Dry, S., Bhushan, A., & Elashoff, R. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1591-5 · Cited by 69

Obesity treatment: novel peripheral targets

Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64

Potential side effects to GLP-1 agonists: understanding their safety and tolerability

Consoli, A., & Formoso, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 65

Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies

Wang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12386 · Cited by 62

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

Gurney, K., MacConell, L., Brown, C. J., & Han, J. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s28387 · Cited by 62

Exenatide-Induced Acute Pancreatitis

Ayoub, W. A., Kumar, A. A., Naguib, H. S., & Taylor, H. C. (2010) · Endocrine Practice · doi:10.4158/ep09104.crr · Cited by 58

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

Gaal, L. F. V., Gutkin, S. W., & Nauck, M. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0804 · Cited by 58

Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity

Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 59

No evidence of drug‐induced pancreatitis in rats treated with exenatide for 13 weeks

Tatarkiewicz, K., Belanger, P., Gu, G., Parkes, D., & Roy, D. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12040 · Cited by 56

The nonhuman primate as a model for type 2 diabetes

Pound, L. D., Kievit, P., & Grove, K. L. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000043 · Cited by 54

Insulin Glargine: a review 8 years after its introduction

Goykhman, S., Drincic, A., Desmangles, J., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49

Evaluation of miR-216a and miR-217 as potential biomarkers of acute pancreatic injury in rats and mice

Goodwin, D., Rosenzweig, B. A., Zhang, J., Xu, L., Stewart, S. R., Thompson, K. L., & Rouse, R. L. (2014) · Biomarkers · doi:10.3109/1354750x.2014.944217 · Cited by 48

GLP-1–Based Therapies: The Dilemma of Uncertainty

Spranger, J., Gundert‐Remy, U., & Stammschulte, T. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.019 · Cited by 48

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry

Montilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., Melchiorri, D., & Pani, L. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.014 · Cited by 46

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

Gurney, K., MacConell, L., Malloy, J. L., Zhou, M., & Kolterman, O. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s77290 · Cited by 48

Is there a place for incretin therapies in obesity and prediabetes?

Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 44

Vildagliptin-Induced Acute Pancreatitis

Girgis, C. M., & Champion, B. L. (2011) · Endocrine Practice · doi:10.4158/ep10383.cr · Cited by 43

High fat diet and GLP-1 drugs induce pancreatic injury in mice

Rouse, R. L., Xu, L., Stewart, S. R., & Zhang, J. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.01.021 · Cited by 42

Ghrelin and New Metabolic Frontiers

van der Lely, A. J. (2009) · Hormone Research in Paediatrics · doi:10.1159/000178055 · Cited by 42

Incretin-based therapies in the treatment of type 2 diabetes — More than meets the eye?

Łabuzek, K., Kozłowski, M., Szkudłapski, D., Sikorska, P., Kozłowska-Geller, M. A., & Okopień, B. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.009 · Cited by 42

Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus

Wajcberg, E., & Tavaria, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802611832 · Cited by 41

The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes

Russell-Jones, D. L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 40

Chemical modification of Class II G protein-coupled receptor ligands: Frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies

Chapter, M. C., White, C. M., DeRidder, A. M., Chadwick, W., Martin, B., & Maudsley, S. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.006 · Cited by 41

Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance

Jung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38

Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis

Cao, M., Pan, C., Tian, Y., Wang, L., Zhao, Z., & Zhu, B. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01556-2 · Cited by 39

Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia

Mondragon, A., Davidsson, D., Kyriakoudi, S., Bertling, A., Gomes-Faria, R., Cohen, P., ROTHERY, S. M., CHABOSSEAU, P. L., Rutter, G. A., & Xavier, G. D. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104873 · Cited by 39

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes

Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Nauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis

Guo, H., Guo, Q., Li, Z., & Wang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1461398 · Cited by 37

Pancreatitis: A Potential Complication of Liraglutide?

Franks, A. S., Lee, P. H., & George, C. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q789 · Cited by 34

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

Ryder, R. E. J., Thong, K. Y., CULL, M. L., Mills, A., Walton, C., & Winocour, P. H. (2010) · Practical Diabetes · doi:10.1002/pdi.1522 · Cited by 33

Collateral damage: the conundrum of drug safety

Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1491-8 · Cited by 31

Exenatide-Induced Chronic Damage of Pancreatic Tissue in Rats

Yu, X., Huayong, T., Huang, L., Yang, Y., Tian, B., & Yu, C. (2012) · Pancreas · doi:10.1097/mpa.0b013e31824e67a3 · Cited by 30

GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment

Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 32

Efficacy and tolerability of the subcutaneous semaglutide for type 2 diabetes patients: an updated systematic review and meta-analysis

Hu, S., Su, X., & Fan, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28

Effect of exendin (exenatide)—GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model

Bulchandani, D., Nachnani, J. S., Herndon, B., Molteni, A., Pathan, M. H., Quinn, T., Hamdan, H. A., Alba, L. M., & Graves, L. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.024 · Cited by 27

Antihyperglycaemic therapies and cancer risk

Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 28

Exenatide and pancreatitis: an update

Bain, S. C., & Stephens, J. W. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802432003 · Cited by 27

Autophagy in Pancreatic Acinar Cells in Caerulein-treated Mice

Zhang, L. W., Zhang, J., Shea, K. I., Xu, L., Tobin, G., Knapton, A. D., Stewart, S. R., & Rouse, R. L. (2013) · Toxicologic Pathology · doi:10.1177/0192623313486967 · Cited by 26

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pieters-van den Bos, I. C., Vendrik, K. E. W., Hoekstra, T., Bruno, M. J., Diamant, M., van Raalte, D. H., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0836 · Cited by 23

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

Samuel, S. M., Varghese, E., Kubatka, P., & Büsselberg, D. (2022) · Biomolecules · doi:10.3390/biom12111580 · Cited by 22

A pooled analysis of exenatide use and risk of acute pancreatitis

Dore, D. D., Hussein, M., Hoffman, C., Pelletier, E. M., Smith, D. B., & Seeger, J. D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.838550 · Cited by 21

Safety and tolerability of glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program

Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin‐based therapies

Ueberberg, S., Jütte, H., Uhl, W. H., Schmidt, W. E., Nauck, M. A., Montanya, E., Tannapfel, A., & Meier, J. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12766 · Cited by 19

Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER

Gigoux, V., & Fourmy, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00050 · Cited by 20

Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan

Tseng, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1091944 · Cited by 18

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

Garg, R. K., Hussey, C., & Ibrahim, S. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02950.x · Cited by 18

Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice

Cox, A. R., Lam, C. J., Rankin, M. M., Rios, J. S., Chavez, J., Bonnyman, C. W., King, K. B., Wells, R. A., Anthony, D., Tu, J. X., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00027 · Cited by 19

GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion

Yang, Y., Yu, X., Huang, L., & Yu, C. (2013) · Pancreatology · doi:10.1016/j.pan.2013.07.281 · Cited by 15

Defining the Role of Basal and Prandial Insulin for Optimal Glycemic Control

Horton, E. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.008 · Cited by 15

Incretin mimetics and acute pancreatitis: enemy or innocent bystander?

Pratley, R. E., Saeed, Z. I., & Casu, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001057 · Cited by 15

The glucagon‐like peptide‐1‐based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys

Roy, D., Chadwick, K. D., Tatarkiewicz, K., LaCerte, C., Bergholm, A., Brodie, T., Mangipudy, R. S., Parkes, D. G., Graziano, M. J., & Reilly, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12294 · Cited by 13

Antidiabetic therapy in post kidney transplantation diabetes mellitus

Werzowa, J. M., Säemann, M. D., Haidinger, M., Krebs, M., & Hecking, M. (2015) · Transplantation Reviews · doi:10.1016/j.trre.2015.01.001 · Cited by 13

Treatment with Ω-3 fatty acids but not exendin-4 improves hepatic steatosis

Bulchandani, D. G., Nachnani, J. S., Nookala, A., Naumovitch, C., Herndon, B., Molteni, A., Quinn, T., & Alba, L. M. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32833b257a · Cited by 12

An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks

Usborne, A. L., Byrd, R. A., Meehan, J., Blackbourne, J. L., Sullivan, J., Poitout‐Belissent, F., Préfontaine, A., Martin, J. A., & Vahle, J. L. (2015) · Toxicologic Pathology · doi:10.1177/0192623315596857 · Cited by 12

Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys

Vahle, J. L., Byrd, R. A., Blackbourne, J. L., Martin, J. A., Sorden, S. D., Ryan, T. E., Pienkowski, T. P., Rosol, T. J., Snyder, P. W., & Klöppel, G. (2015) · Toxicologic Pathology · doi:10.1177/0192623315588999 · Cited by 11

Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance

Wang, Y., Qi, M., McGarrigle, J. J., Rady, B., Davis, M., Vaca, P., & Oberholzer, J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0402-z · Cited by 11

Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects

Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10

Safety and adverse effects associated with GLP-1 analogues

Stephens, J. W., & Bain, S. C. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.4.417 · Cited by 10

Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus

Wajcberg, E., & Tavaria, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802611832 · Cited by 41

Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24

Exenatide-Associated Ischemic Renal Failure

Weise, W. J., Sivanandy, M. S., Block, C. A., & Comi, R. J. (2009) · Diabetes Care · doi:10.2337/dc08-1309 · Cited by 99

Elevated Pancreatic Enzymes and Acute Pancreatitis in Subjects with Type 2 Diabetes Mellitus Treated with Exenatide

Kabadi, U. M. (2017) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2017.03.555609

Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus

Triplitt, C. L., & DeFronzo, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.3.329 · Cited by 25